AR and prostate cancer: Both compounds were evaluated in five human prostate cancer cell lines known for different resistance profiles: LNCaP (AR-FL+ and AR-V7−, androgen-dependent, docetaxel-sensitive), 22Rv1 and VCaP (AR-FL+ and AR-V7+, androgen-independent, docetaxel-sensitive), and PC-3 and DU145 (AR-FL− and AR-V7−, androgen-independent, docetaxel-resistant) [29,30].